CA2282691A1 - Derives d'acide amine heterocyclique antibacterien - Google Patents

Derives d'acide amine heterocyclique antibacterien Download PDF

Info

Publication number
CA2282691A1
CA2282691A1 CA002282691A CA2282691A CA2282691A1 CA 2282691 A1 CA2282691 A1 CA 2282691A1 CA 002282691 A CA002282691 A CA 002282691A CA 2282691 A CA2282691 A CA 2282691A CA 2282691 A1 CA2282691 A1 CA 2282691A1
Authority
CA
Canada
Prior art keywords
alkyl
formula
compound
hydrogen
vivo hydrolysable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002282691A
Other languages
English (en)
Inventor
Martin Leonard Gilpin
John Hargreaves Bateson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2282691A1 publication Critical patent/CA2282691A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé pour le traitement d'infections bactériennes chez l'homme ou chez l'animal. Ce procédé consiste à administrer, en association avec un antibiotique .beta.-lactame, une quantité thérapeutiquement efficace d'un dérivé d'acide aminé ou d'un sel pharmaceutiquement acceptable, un solvate ou un ester hydrolysable in vivo de ce dernier: (i) ou (ii) où X représente S, S(O)¿p? ou CH¿2? où p est égal à 1 ou 2; R est hydrogène, un sel formant cation ou un groupe formant ester pouvant être hydrolysé in vivo; R¿1? et R¿2? sont choisis parmi halogène, mercapto, alkyle (C¿1-6?) éventuellement substitué par halo 1-3, phényle, alcoxy (C¿1-6?) éventuellement substitué par halo 1-3, hydroxy (C¿1-6?)alkyle, mercapto (C¿1-6?) alkyle, hydroxy, CO¿2?R¿7?, N(R¿7?)¿2? ou CON(R¿7?)¿2? où chaque R¿7? est indépendamment hydrogène ou des groupes alkyle (C¿1-6?), OCONH¿2?, nitro, alkylcarbonyloxy (C¿1-6?), alcoxycarbonyl(C¿1-6?) alkyle, formyl, ou alkylcarbonyl (C¿1-6?); R¿3? représente hydrogène, alkyle(C¿1-6?) éventuellement substitué par jusqu'à trois atomes d'halogène, cycloalkyle (C¿3-7?), aryle (C¿3-7?)cycloalkyle fondu, cycloalkyle(C¿3-7?) alkyle(C¿2-6?), alkényle (C¿2-6?), alkynyle (C¿2-6?), aryle, aryle-(CHR¿10?)¿m?-X¿1?-(CHR¿11?)¿n?, hétérocyclyle ou hétérocyclyle-(CHR¿10?)¿m?-X¿1?-(CHR¿11?)¿n?, où m est compris entre 0 et 3, n est compris entre 1 et 3, chaque R¿10? et R¿11? est indépendamment de l'hydrogène ou alkyle (C¿1-4?) et X¿1? est O, S(O)¿x? où x est égal à 0-2, ou une liaison; R¿4? est hydrogène, ou un groupe acyle hydrolysable in vivo; et R¿5? et R¿6? sont indépendamment de l'hydrogène et alkyle (C¿1-6?) ou ensemble représentent (CH¿2?)q où q est égal à 2 à 5.
CA002282691A 1997-03-05 1998-02-25 Derives d'acide amine heterocyclique antibacterien Abandoned CA2282691A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9704522.3 1997-03-05
GBGB9704522.3A GB9704522D0 (en) 1997-03-05 1997-03-05 Compounds
PCT/EP1998/001278 WO1998039311A1 (fr) 1997-03-05 1998-02-25 Derives d'acide amine heterocyclique antibacterien

Publications (1)

Publication Number Publication Date
CA2282691A1 true CA2282691A1 (fr) 1998-09-11

Family

ID=10808715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002282691A Abandoned CA2282691A1 (fr) 1997-03-05 1998-02-25 Derives d'acide amine heterocyclique antibacterien

Country Status (5)

Country Link
EP (1) EP0968199A1 (fr)
JP (1) JP2001515477A (fr)
CA (1) CA2282691A1 (fr)
GB (1) GB9704522D0 (fr)
WO (1) WO1998039311A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630510B1 (en) 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
AU2006293023A1 (en) 2005-09-22 2007-03-29 Meiji Seika Kaisha, Ltd. Metallo-beta-lactamase inhibitors
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU509899B2 (en) * 1976-02-13 1980-05-29 E.R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4283407A (en) * 1977-09-28 1981-08-11 Science Union Et Cie Thiopropionamides, and the pharmaceutical compositions
DE3044236A1 (de) * 1980-11-25 1982-06-16 Hoechst Ag, 6000 Frankfurt Aminosaeurederivate und verfahren zu ihrer herstellung
FR2487829A2 (fr) * 1979-12-07 1982-02-05 Science Union & Cie Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
DE3161915D1 (en) * 1980-03-05 1984-02-23 Univ Miami Angiotensin converting enzyme inhibitors
WO1997010225A1 (fr) * 1995-09-15 1997-03-20 Smithkline Beecham Plc Derives de pyrrolidine et de thiazole ayant des proprietes antibacteriennes et d'inhibition de la metallo-betalactamase

Also Published As

Publication number Publication date
WO1998039311A1 (fr) 1998-09-11
GB9704522D0 (en) 1997-04-23
EP0968199A1 (fr) 2000-01-05
JP2001515477A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
JP2003513890A (ja) 新規なコハク酸系メタロ−β−ラクタマーゼ阻害薬およびそれの細菌感染治療での使用
US6022885A (en) Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties
US6600035B1 (en) 6-(substituted methylene) penems and intermediates
US6048852A (en) β-thiopropionyl-aminoacid derivatives and their use as β-lactamase inhibitors
EP1227721B1 (fr) Nouveaux inhibiteurs de metallo-beta-lactamases d'acide succinique substitues et leur utilisation dans le traitement d'infections bacteriennes
US6156774A (en) Beta-thiopropionyl-amino acid derivatives and their use as beta-lactamase inhibitors
US6211212B1 (en) Pyrrolidine and thiazole derivatives with metallo-beta-lactamase inhibitory properties
CA2282691A1 (fr) Derives d'acide amine heterocyclique antibacterien
US4562182A (en) Compounds containing beta-lactams
EP0167050A1 (fr) Clavulanates, leur préparation et application ainsi que leurs produits intermédiaires
CA2298682A1 (fr) Acides mercapto-acyl-amines utilises comme inhibiteurs des metallo-beta lactamases
EP0112685B1 (fr) Composés contenant des bêta-lactames
AU715163B2 (en) 6-(substituted methylene) penems and intermediates
EP0068609A1 (fr) Dérivés de l'acide clavulanique, un procédé pour leur préparation et leur application
JPH11514981A (ja) 抗菌およびメタロ−β−ラクタマーゼ阻害特性を有するピロリジンおよびチアゾール誘導体
EP0127636A1 (fr) Composes contenant des beta-lactames

Legal Events

Date Code Title Description
FZDE Dead